Company profile
Genelux Corporation
NASDAQ: GNLX · Healthcare · Biotechnology
#1136 of 1,418 Healthcare companies by revenue41st-percentile growth
EA Score
32DFH 27DQ 38GM 34SS 39
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, market scale · ↓ operating margin, net margin
Methodology →Revenue TTM
$8.0k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$32.1M
Employees
26
as of 2026-08-18
Market cap
$118.6M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$8.0k$8.0k2025
Net income-$32.1M-$32.1M2025
Operating income-$33.2M-$33.2M2025
Total assets$19.0M$19.0M2025
Liabilities$7.5M$7.5M2025
Equity$11.5M$11.5M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Genelux Corporation’s revenue?
Genelux Corporation booked $8.0k in FY2025 revenue, growing 0.0% year over year — about the middle of the pack among Healthcare companies we track, at a -401812.5% net margin.
Peers · Healthcare
SYBLEU Inc——Modern Mobility Aids, Inc.——Voyageur Pharmaceuticals Ltd.——Better Therapeutics, Inc.——Kaya Holdings, Inc.——Aspire Biopharma Holdings, Inc.17DNeighbors
Los Angeles →Key facts
CEOThomas D. Zindrick
SectorHealthcare
IndustryBiotechnology
HeadquartersWestlake Village, CA
ExchangeNASDAQ: GNLX
Employees26
IPO date2023-01-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.